“The combination program for the diabetes vaccine Diamyd® is of interest to both researchers and industry,” says Anders Essen-MÖller, Chairman of
Type 1 diabetes is an autoimmune disease where the immune system attacks the patients’ own insulin producing beta cells. For these patients, daily treatment with insulin is mandatory to sustain life. The importance of finding a cure is high for the world’s health care systems and the wellbeing of patients. The annual market for an easy to use, successful therapeutic is estimated to several billion dollars.
About Diamyd® Diamyd® is a therapeutic under development for the treatment and prevention of autoimmune diabetes. Diamyd® has been used in trials totaling more than one thousand patients with an excellent safety profile. Diamyd has shown an overall 16% efficacy (p=0.1) versus placebo regarding preservation of the patients’ endogenous insulin secretion in a European Phase III trial and is currently being further developed in combination regimens with other therapeutic compounds. Diamyd® is easy to administer in any clinical setting. For further information, please contact: Anders Essen-MÖller, Chairman Diamyd Medical AB Phone: +46 70 55 10 679. E-mail: email@example.com About Diamyd Medical Diamyd Medical is dedicated to fight type 1 diabetes and to work towards a cure for the disease. Diamyd Medical’s current projects include development of combination regimens for arresting the successive destruction of insulin producing beta cells using the Company’s GAD65 -based diabetes vaccine, such as for example Diamyd®+ Vitamin D with or without an anti-inflammatory compound; and Diamyd®+ GABA, for which
This information was brought to you by
The following files are available for download:
Most Popular Stories
- Frightfully Fun Films Return for Halloween
- Hollywood Eager to Grasp Hispanic Market
- Cape Cod Building Mussel Industry
- Cloud Lifts Microsoft's Quarterly Results
- Would Soccer Be Richer Without Small Clubs?
- Weekly Jobless Claims Rise but Remain Low
- Pfizer Approves $11 Billion Buyback Plan
- IS Funded by Black Market Oil Sales, Racketeering
- Sears Denies Store Closings, Layoffs Report
- Teresa Giudice Must Serve Time in Prison